Ameriprise
GYRE icon

Ameriprise’s Gyre Therapeutics GYRE Stock Holding History

Ameriprise’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-6,451
Closed -$244K – 3922
2021
Q1 		$244K Sell
6,451
-80
-1% -$3.66K ﹤0.01% 3658
2020
Q4 		$309K Buy
6,531
+4,860
+291% +$210K ﹤0.01% 3496
2020
Q3 		$54K Buy
1,671
+159
+11% +$6.22K ﹤0.01% 3673
2020
Q2 		$67K Buy
+1,512
New +$71K ﹤0.01% 3607
2014
Q3 		– Hold
0
– -$1K – 5836
2014
Q2 		– Hold
0
– – – 5346
2013
Q4 		– Sell
-2
Closed -$9K – 5258
2013
Q3 		$9K Hold
2
– – ﹤0.01% 4973
2013
Q2 		$7K Buy
+2
New +$7.61K ﹤0.01% 4989

Other funds holding GYRE

SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Ameriprise's GYRE Position: Q2 2021 in Review

Ameriprise sold out of Gyre Therapeutics (GYRE) in Q2 2021, closing a stake of 6,451 shares — an estimated $244K sold.

Ameriprise first reported a position in GYRE in Q2 2013 and held it in 6 quarters. The position peaked at $309K in Q4 2020. 69 funds tracked by Wall St. Rank hold GYRE as of Q2 2021.

  • Ameriprise reported no remaining Gyre Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Ameriprise sold 6,451 Gyre Therapeutics shares in Q2 2021, an estimated $244K.
  • Ameriprise first reported a position in Gyre Therapeutics in Q2 2013 and held it in 6 quarters.
  • Ameriprise's Gyre Therapeutics position peaked at $309K in Q4 2020.
  • 69 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2021.

Based on Ameriprise's 13F filing for Q2 2021, filed 16 Aug 2021.